SCHEMBL30531780

CC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccc(O)c(I)c1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCN(CCNC(C)(C)/C(C)=N\O)CCNC(C)(C)/C(C)=N\O)[C@@H](C)O)C(C)C

nearest known ligand 0.53

Predicted protein targets (top 10)

	gene	UniProt	supporting neighbours	confidence
▸	TFPI	P10646	7/20	0.53

▸	OPRM1	P35372	2/20	0.49

▸	OPRD1	P41143	2/20	0.49

▸	OPRK1	P41145	2/20	0.49

▸	NPY2R	P49146	7/20	0.49

▸	NPY4R	P50391	7/20	0.49

▸	NPY5R	Q15761	7/20	0.49

▸	NPY1R	P25929	5/20	0.49

▸	KDM1A	O60341	2/20	0.49

▸	F2	P00734	1/20	0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL13487335	0.91	TFPI (0.54)	TFPIOPRM1OPRD1OPRK1NPY2R
SCHEMBL13645144	0.87	NPY2R (0.48)	TFPIOPRM1OPRD1OPRK1NPY2R
SCHEMBL31745635	0.77	NPY2R (0.64)	TFPINPY2RNPY4RNPY5RNPY1R
SCHEMBL29352561	0.76	KEAP1 (0.64)	OPRM1OPRD1OPRK1F2
SCHEMBL19709276	0.76	KDM1A (0.61)	TFPINPY2RNPY4RNPY5RNPY1R
SCHEMBL19709273	0.76	KDM1A (0.60)	TFPINPY2RNPY4RNPY5RNPY1R
SCHEMBL29405698	0.76	TFPI (0.70)	TFPINPY2RNPY4RNPY5RNPY1R
SCHEMBL30607403	0.75	CALCR (0.67)	TFPIOPRM1OPRD1OPRK1NPY2R
SCHEMBL31182783	0.75	CALCR (0.63)	TFPINPY2RNPY4RNPY5RNPY1R
SCHEMBL31688332	0.75	OPRM1 (0.61)	OPRM1OPRD1OPRK1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-3129065-B1	TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS	AKAMARA THERAPEUTICS INC (US)	2026-05-13	—	—	EP	disclosed
US-11701429-B2	Targeted drug delivery through affinity based linkers	Akamara Therapeutics, Inc. (US)	2023-07-18	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11701429-B2	Targeted drug delivery through affinity based linkers	ABCG2, FCGR2A, ABCB1	TFPI 3101/4885OPRM1 2364/4885OPRD1 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.